David W Dempster

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/3478679/david-w-dempster-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

 139
 15,026
 58
 122

 papers
 citations
 h-index
 g-index

 150
 16,872
 6
 6.09

 ext. papers
 ext. citations
 avg, IF
 L-index

#	Paper	IF	Citations
139	Effects of teriparatide and loading modality on modeling-based and remodeling-based bone formation in the human femoral neck <i>Bone</i> , 2022 , 116342	4.7	O
138	Whole exome sequencing reveals potentially pathogenic variants in a small subset of premenopausal women with idiopathic osteoporosis. <i>Bone</i> , 2022 , 154, 116253	4.7	2
137	Ten-Year Simulation of the Effects of Denosumab on Bone Remodeling in Human Biopsies. <i>JBMR Plus</i> , 2021 , 5, e10494	3.9	1
136	Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal Women With Osteoporosis in the Phase 3 Long-Term Odanacatib Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 1225-1234	6.3	2
135	Mineral and organic matrix composition at bone forming surfaces in postmenopausal women with osteoporosis treated with either teriparatide or zoledronic acid. <i>Bone</i> , 2021 , 145, 115848	4.7	4
134	Bone Marrow Adiposity in Premenopausal Women With Type 2 Diabetes With Observations on Peri-Trabecular Adipocytes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3592-e3602	5.6	1
133	Lessons from bone histomorphometry on the mechanisms of action of osteoporosis drugs 2021 , 1835-	1863	1
132	Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2021 , 36, 644-653	6.3	9
131	The nature of osteoporosis 2021 , 3-13		
130	Anabolic Agents for Postmenopausal Osteoporosis: How Do You Choose?. <i>Current Osteoporosis Reports</i> , 2021 , 19, 189-205	5.4	5
129	No evidence for alteration in early secondary mineralization by either alendronate, teriparatide or combination of both in transiliac bone biopsy samples from postmenopausal osteoporotic patients. <i>Bone Reports</i> , 2020 , 12, 100253	2.6	4
128	Modeling-Based Bone Formation in the Human Femoral Neck in Subjects Treated With Denosumab. Journal of Bone and Mineral Research, 2020 , 35, 1282-1288	6.3	15
127	Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 1289-1299	6.3	6
126	A microRNA Approach to Discriminate Cortical Low Bone Turnover in Renal Osteodystrophy. <i>JBMR Plus</i> , 2020 , 4, e10353	3.9	4
125	Loading modality and age influence teriparatide-induced bone formation in the human femoral neck. <i>Bone</i> , 2020 , 136, 115373	4.7	2
124	PTH as An Anabolic Agent 2020 , 623-630		
123	Histomorphometric analysis of bone remodeling 2020 , 445-467		

122	Effect of Teriparatide on Bone Remodeling and Density in Premenopausal Idiopathic Osteoporosis: A Phase II Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	7
121	Standard Versus Cyclic Teriparatide and Denosumab Treatment for Osteoporosis: A Randomized Trial. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 219-225	6.3	11
120	Women With Pregnancy and Lactation-Associated Osteoporosis (PLO) Have Low Bone Remodeling Rates at the Tissue Level. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1552-1561	6.3	18
119	Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 626-637	1 ^{6.3}	8
118	Administration of teriparatide for four years cyclically compared to two years daily in treatment NaWe and alendronate treated women. <i>Bone</i> , 2019 , 120, 246-253	4.7	10
117	Bone Matrix Mineralization in Patients With Gain-of-Function Calcium-Sensing Receptor Mutations Is Distinctly Different From that in Postsurgical Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 661-668	6.3	3
116	Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 298-306	6.3	48
115	Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 2498-2509	5.6	51
114	Bone Histomorphometry 2018 , 959-973		4
113	The trabecular bone score: Relationships with trabecular and cortical microarchitecture measured by HR-pQCT and histomorphometry in patients with chronic kidney disease. <i>Bone</i> , 2018 , 116, 215-220	4.7	31
112	Longitudinal Effects of Teriparatide or Zoledronic Acid on Bone Modeling- and Remodeling-Based Formation in the SHOTZ Study. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 627-633	6.3	32
111	The Effects of Long-term Administration of rhPTH(1-84) in Hypoparathyroidism by Bone Histomorphometry. <i>Journal of Bone and Mineral Research</i> , 2018 , 33, 1931-1939	6.3	20
110	Parathyroid Hormone Directs Bone Marrow Mesenchymal Cell Fate. <i>Cell Metabolism</i> , 2017 , 25, 661-672	24.6	208
109	IGF-1 Receptor Expression on Circulating Osteoblast Progenitor Cells Predicts Tissue-Based Bone Formation Rate and Response to Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1267-1273	6.3	8
108	Tethering Formation to Resorption: Reversal Revisited. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 1389-1390	6.3	7
107	10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. <i>Lancet Diabetes and Endocrinology,the</i> , 2017 , 5, 513-523	18.1	419
106	Treatment Sequence Matters: Anabolic and Antiresorptive Therapy for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 198-202	6.3	132
105	Fragility Fracture Incidence in Chronic Obstructive Pulmonary Disease (COPD) Patients Associates With Nanoporosity, Mineral/Matrix Ratio, and Pyridinoline Content at Actively Bone-Forming Trabecular Surfaces. <i>Journal of Bone and Mineral Research</i> , 2017 , 32, 165-171	6.3	9

104	Effect of Teriparatide on Bone Formation in the Human Femoral Neck. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1498-505	5.6	26
103	Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 1353-63	5.6	42
102	Presentation of Hypoparathyroidism: Etiologies and Clinical Features. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2300-12	5.6	175
101	Effects of Parathyroid Hormone Administration on Bone Strength in Hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1082-8	6.3	13
100	Aging Versus Postmenopausal Osteoporosis: Bone Composition and Maturation Kinetics at Actively-Forming Trabecular Surfaces of Female Subjects Aged 1 to 84 Years. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 347-57	6.3	45
99	Effects of Daily or Cyclic Teriparatide on Bone Formation in the Iliac Crest in Women on No Prior Therapy and in Women on Alendronate. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1518-26	6.3	29
98	Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2016 , 8, 225-235	3.8	198
97	PTH(1-84) Administration in Hypoparathyroidism Transiently Reduces Bone Matrix Mineralization. Journal of Bone and Mineral Research, 2016 , 31, 180-9	6.3	21
96	A Longitudinal Study of Skeletal Histomorphometry at 6 and 24 Months Across Four Bone Envelopes in Postmenopausal Women With Osteoporosis Receiving Teriparatide or Zoledronic Acid in the SHOTZ Trial. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1429-39	6.3	40
95	Differential Effects of Teriparatide and Zoledronic Acid on Bone Mineralization Density Distribution at 6 and 24 Months in the SHOTZ Study. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1527-35	6.3	36
94	Daily or Cyclical Teriparatide Treatment in Women With Osteoporosis on no Prior Therapy and Women on Alendronate. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015 , 100, 2769-76	5.6	29
93	Bone Physiology: Bone Cells, Modeling, and Remodeling 2015 , 37-56		4
92	Bone Density After Teriparatide Discontinuation in Premenopausal Idiopathic Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2015 , 100, 4208-14	5.6	30
91	Bone Histomorphometry and Bone Quality in Primary Hyperparathyroidism 2015 , 429-445		5
90	Sustained Modeling-Based Bone Formation During Adulthood in Cynomolgus Monkeys May Contribute to Continuous BMD Gains With Denosumab. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1280-9	6.3	76
89	Effects of up to 5 years of denosumab treatment on bone histology and histomorphometry: the FREEDOM study extension. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 2051-6	6.3	47
88	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3580-94	5.6	227
87	Increased IL-6 expression in osteoclasts is necessary but not sufficient for the development of Paget B disease of bone. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1456-65	6.3	22

86	Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts. <i>Blood</i> , 2014 , 124, 2834-46	2.2	85
85	Autophagy in osteoblasts is involved in mineralization and bone homeostasis. <i>Autophagy</i> , 2014 , 10, 196	5:72	214
84	Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 2418-25	5.6	37
83	Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2014 , 29, 1-23	6.3	935
82	Lessons from Bone Histomorphometry on the Mechanisms of Action of Osteoporosis Drugs 2013 , 1777	'-1803	О
81	Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2-17	6.3	1588
80	Role of ATF7-TAF12 interactions in the vitamin D response hypersensitivity of osteoclast precursors in Paget® disease. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 1489-500	6.3	12
79	Teriparatide for idiopathic osteoporosis in premenopausal women: a pilot study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 1971-81	5.6	64
78	Abdominal fat is associated with lower bone formation and inferior bone quality in healthy premenopausal women: a transiliac bone biopsy study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013 , 98, 2562-72	5.6	129
77	Double and quadruple tetracycline labeling of bone: impact of the label itself. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 222-3	6.3	11
76	Benefits and risks of bisphosphonate therapy for osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2272-82	5.6	190
75	Bone material properties in premenopausal women with idiopathic osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 2551-61	6.3	68
74	Patient-specific bone modelling and remodelling simulation of hypoparathyroidism based on human iliac crest biopsies. <i>Journal of Biomechanics</i> , 2012 , 45, 2411-6	2.9	25
73	Parathyroid hormone treatment improves the cortical bone microstructure by improving the distribution of type I collagen in postmenopausal women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 702-12	6.3	22
72	Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure. <i>Journal of Bone and Mineral Research</i> , 2012 , 27, 1811-20	6.3	57
71	Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data. <i>Clinical Therapeutics</i> , 2012 , 34, 521-36	3.5	84
7°	Central QCT reveals lower volumetric BMD and stiffness in premenopausal women with idiopathic osteoporosis, regardless of fracture history. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 4244-52	5.6	27
69	Increased marrow adiposity in premenopausal women with idiopathic osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2782-91	5.6	78

68	Skeletal histomorphometry in subjects on teriparatide or zoledronic acid therapy (SHOTZ) study: a randomized controlled trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012 , 97, 2799-808	5.6	73
67	Contributions of the measles virus nucleocapsid gene and the SQSTM1/p62(P392L) mutation to Paget B disease. <i>Cell Metabolism</i> , 2011 , 13, 23-34	24.6	90
66	Vitamin D deficiency influences histomorphometric features of bone in primary hyperparathyroidism. <i>Bone</i> , 2011 , 48, 557-61	4.7	53
65	Bone remodeling in postmenopausal women who discontinued denosumab treatment: off-treatment biopsy study. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2737-44	6.3	50
64	PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2727-36	6.3	104
63	Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2317-37	6.3	369
62	Abnormal bone microarchitecture and evidence of osteoblast dysfunction in premenopausal women with idiopathic osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3095-1	105 ⁶	58
61	Osteoporosis and the burden of osteoporosis-related fractures. <i>American Journal of Managed Care</i> , 2011 , 17 Suppl 6, S164-9	2.1	72
60	Bone histomorphometry: a concise review for endocrinologists and clinicians. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2010 , 54, 87-98		63
59	Three dimensional cancellous bone structure in hypoparathyroidism. <i>Bone</i> , 2010 , 46, 190-5	4.7	71
58	Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2256-65	6.3	173
57	Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 2267-94	6.3	840
56	Skeletal microstructural abnormalities in postmenopausal women with chronic obstructive pulmonary disease. <i>Journal of Bone and Mineral Research</i> , 2010 , 25, 1931-40	6.3	38
55	Bisphosphonate associated osteonecrosis of the jaw. <i>Journal of Rheumatology</i> , 2009 , 36, 478-90	4.1	131
54	PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 964-73	6.3	62
53	Assessing fracture risk and effects of osteoporosis drugs: bone mineral density and beyond. <i>American Journal of Medicine</i> , 2009 , 122, 992-7	2.4	17
52	TNFalpha receptor knockout in mice reduces adverse effects of magnesium deficiency on bone. <i>Growth Factors</i> , 2009 , 27, 370-6	1.6	10
51	Histomorphometric Analysis of Bone Remodeling 2008 , 447-463		2

50	A SQSTM1/p62 mutation linked to Paget® disease increases the osteoclastogenic potential of the bone microenvironment. <i>Human Molecular Genetics</i> , 2008 , 17, 3708-19	5.6	74
49	Bone quality determined by Fourier transform infrared imaging analysis in mild primary hyperparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008 , 93, 3484-9	5.6	20
48	Dynamic and structural properties of the skeleton in hypoparathyroidism. <i>Journal of Bone and Mineral Research</i> , 2008 , 23, 2018-24	6.3	141
47	Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology, 2008 , 35, 1391-7	4.1	111
46	Increased resorptive activity and accompanying morphological alterations in osteoclasts derived from the oim/oim mouse model of osteogenesis imperfecta. <i>Journal of Cellular Biochemistry</i> , 2007 , 102, 1011-20	4.7	18
45	Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 495-502	6.3	205
44	New observations on bone quality in mild primary hyperparathyroidism as determined by quantitative backscattered electron imaging. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 717-23	6.3	63
43	The effects of combination of alendronate and human parathyroid hormone(1-34) on bone strength are synergistic in the lumbar vertebra and additive in the femur of C57BL/6J mice. <i>Endocrinology</i> , 2007 , 148, 4466-74	4.8	30
42	Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity. <i>Bone</i> , 2007 , 40, 391-8	4.7	30
41	Recovery from skeletal fluorosis (an enigmatic, American case). <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 163-70	6.3	45
40	Mutation of the sequestosome 1 (p62) gene increases osteoclastogenesis but does not induce Paget disease. <i>Journal of Clinical Investigation</i> , 2007 , 117, 133-42	15.9	97
39	Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis. <i>Journal of Clinical Densitometry</i> , 2006 , 9, 58-65	3.5	13
38	The development of parathyroid hormone as anabolic therapy for osteoporosis. <i>Clinical Reviews in Bone and Mineral Metabolism</i> , 2006 , 4, 227-232	2.5	1
37	Effects of cyclic versus daily hPTH(1-34) regimens on bone strength in association with BMD, biochemical markers, and bone structure in mice. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 274-82	<u>,</u> 6.3	34
36	Expression of measles virus nucleocapsid protein in osteoclasts induces Pagetß disease-like bone lesions in mice. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 446-55	6.3	81
35	A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. <i>Journal of Bone and Mineral Research</i> , 2006 , 21, 366-73	6.3	218
34	Normal human osteoclasts formed from peripheral blood monocytes express PTH type 1 receptors and are stimulated by PTH in the absence of osteoblasts. <i>Journal of Cellular Biochemistry</i> , 2005 , 95, 139-	.487	66
33	Low bone formation in premenopausal women with idiopathic osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005 , 90, 3331-6	5.6	29

32	Therapeutic potential of curcumin in prostate cancerV: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells. <i>Prostate</i> , 2004 , 60, 1-17	4.2	44
31	Effects of intermittent parathyroid hormone administration on bone mineralization density in iliac crest biopsies from patients with osteoporosis: a paired study before and after treatment. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1150-6	5.6	212
30	Trabecular bone response to mechanical and parathyroid hormone stimulation: the role of mechanical microenvironment. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 2116-25	6.3	85
29	The pathophysiology of bone loss. <i>Clinics in Geriatric Medicine</i> , 2003 , 19, 259-70, v-vi	3.8	22
28	Precision, accuracy, and reproducibility of dual X-ray absorptiometry measurements in mice in vivo. Journal of Clinical Densitometry, 2003 , 6, 25-33	3.5	40
27	Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice. <i>Journal of Bone and Mineral Research</i> , 2002 , 17, 808-16	6.3	118
26	Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. <i>Journal of Bone and Mineral Research</i> , 2001 , 16, 1846-	.633	495
25	The effects of vitamin D insufficiency in patients with primary hyperparathyroidism. <i>American Journal of Medicine</i> , 1999 , 107, 561-7	2.4	187
24	Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. <i>Lancet, The</i> , 1997 , 350, 550-5	40	638
23	Histomorphometric assessment of bone mass, structure, and remodeling: a comparison between healthy black and white premenopausal women. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 948-57	6.3	66
22	Resistance to bone resorbing effects of PTH in black women. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 958-66	6.3	142
21	Tumor-induced osteomalacia: clinical and basic studies. <i>Journal of Bone and Mineral Research</i> , 1997 , 12, 1502-11	6.3	55
20	The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1996 , 39, 277-82		83
19	Zinc is a potent inhibitor of osteoclastic bone resorption in vitro. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 453-7	6.3	217
18	Bone structure in postmenopausal hyperparathyroid, osteoporotic, and normal women. <i>Journal of Bone and Mineral Research</i> , 1995 , 10, 1393-9	6.3	103
17	Hereditary hyperphosphatasia: 20 year follow-up and response to disodium etidronate. <i>Journal of Bone and Mineral Research</i> , 1994 , 9, 733-8	6.3	14
16	Stimulation of bone resorption and osteoclast clear zone formation by low pH: a time-course study. Journal of Cellular Physiology, 1993 , 154, 511-8	7	26
15	Effects of phorbol myristate acetate on rat and chick osteoclasts. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 415-23	6.3	20

LIST OF PUBLICATIONS

14	Effects of heparin on osteoclast activity. Journal of Bone and Mineral Research, 1992, 7, 771-7	6.3	37
13	Maintenance of cancellous bone connectivity in primary hyperparathyroidism: trabecular strut analysis. <i>Journal of Bone and Mineral Research</i> , 1992 , 7, 913-9	6.3	110
12	A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. <i>Journal of Bone and Mineral Research</i> , 1991 , 6, 689-96	6.3	111
11	Characterization and evaluation of asymptomatic primary hyperparathyroidism. <i>Journal of Bone and Mineral Research</i> , 1991 , 6 Suppl 2, S85-9; discussion S121-4	6.3	41
10	Effects of cyclosporine A on chick osteoclasts in vitro. Calcified Tissue International, 1991, 49, 275-9	3.9	37
9	Protons and osteoclasts. <i>Journal of Bone and Mineral Research</i> , 1990 , 5, 1099-103	6.3	43
8	The histomorphometry of bone in primary hyperparathyroidism: preservation of cancellous bone structure. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990 , 70, 930-8	5.6	280
7	Bone histomorphometry in glucocorticoid-induced osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 137-41	6.3	240
6	Bone resorption by isolated human osteoclasts in vitro: effects of calcitonin. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 259-68	6.3	51
5	Skeletal disease in primary hyperparathyroidism. <i>Journal of Bone and Mineral Research</i> , 1989 , 4, 283-91	6.3	425
4	Interaction of calcium nutrition and physical activity on bone mass in young women. <i>Journal of Bone and Mineral Research</i> , 1988 , 3, 145-9	6.3	174
3	A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins. <i>Endocrinology</i> , 1987 , 120, 602-8	4.8	176
2	The effect of oral phosphate administration on major indices of skeletal metabolism in normal subjects. <i>Journal of Bone and Mineral Research</i> , 1986 , 1, 383-8	6.3	59
1	Chapter 20. Age-Related Bone Loss98-102		5